Hong Fan-zhen, Wang Bo, Li Hiu-Ming, Liew Choong-Tsek
Department of Gynaecology, Qilu Hospital of Shandong University, Jinan 250012, China.
Zhonghua Bing Li Xue Za Zhi. 2005 May;34(5):257-61.
The FHIT (fragile histidine triad) is a candidate tumor suppressor gene (TSG) located on chromosome 3p14.2. Hypermethylation and loss of heterozygosity (LOH) are major mechanisms in the inactivation of tumor suppressor genes. In this study, the methylation status of FHIT and LOH of 3p14 in 61 cases of human sporadic ovary carcinomas were investigated.
Sixty-one primary ovary carcinomas and 10 borderline ovarian tumors were analyzed with methylation specific PCR (MSP) to detect the CpG island methylation status in the FHIT promoter region. In addition, 45 cases of ovary carcinomas and their corresponding non-tumor ovary tissues were investigated with D3S1287 microsatellite polymorphic marker for LOH.
Hypermethylation of FHIT gene was observed in 39.3% (24/61) of ovarian carcinomas. The frequencies of hypermethylation in serous ovarian carcinoma, mucinous ovarian carcinoma, endometrioid ovarian carcinoma and ovary borderline tumor were 45.2% (19/42), 14.3% (1/7), 33.3% (4/12) and 60.0% (6/10), respectively. Ten of twenty-three (43.5%) informative tumors showed LOH and 6 of 18 (33.3%) informative cases showed homozygous deletions. The status of FHIT methylation was not associated with clinical stage and differentiation grade, there was no significant difference between the malignant and borderline tumors.
Hypermethylation and allelic deletion of FHIT are frequent events in ovarian carcinomas and are important mechanisms for the loss of expression of this gene.
FHIT(脆性组氨酸三联体)是位于染色体3p14.2上的候选抑癌基因。高甲基化和杂合性缺失(LOH)是抑癌基因失活的主要机制。本研究调查了61例人散发性卵巢癌中FHIT的甲基化状态及3p14的LOH情况。
采用甲基化特异性PCR(MSP)分析61例原发性卵巢癌和10例卵巢交界性肿瘤,以检测FHIT启动子区域的CpG岛甲基化状态。此外,用D3S1287微卫星多态性标记对45例卵巢癌及其相应的非肿瘤卵巢组织进行LOH检测。
39.3%(24/61)的卵巢癌中观察到FHIT基因高甲基化。浆液性卵巢癌、黏液性卵巢癌、子宫内膜样卵巢癌和卵巢交界性肿瘤的高甲基化频率分别为45.2%(19/42)、14.3%(1/7)、33.3%(4/12)和60.0%(6/10)。23例信息充分的肿瘤中有10例(43.5%)显示LOH,18例信息充分的病例中有6例(33.3%)显示纯合缺失。FHIT甲基化状态与临床分期和分化程度无关,恶性肿瘤与交界性肿瘤之间无显著差异。
FHIT的高甲基化和等位基因缺失在卵巢癌中很常见,是该基因表达缺失的重要机制。